Puma Biotechnology, Inc. (PBYI) Stock
Fundamentals
Recent news

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
PBYI

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.06 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
PBYI

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
PBYI

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
PBYI

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
PBYI

Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology Q2 Earnings Call Highlights
PBYI

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
PBYI

Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology Reports Second Quarter 2026 Financial Results
PBYI

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI
About Puma Biotechnology, Inc.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Alan H. Auerbach | Founder, Chairman, President, CEO & Secretary | 1970 |
| Mr. Maximo F. Nougues | CFO & Principal Accounting Officer | 1969 |
| Mr. Douglas Hunt B.Sc., FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer | 1965 |
| Mr. Gordon G. Esplin | Chief Accounting Officer | 1968 |
| Mr. Mariann Ohanesian | Senior Director of Investor Relations | — |
| Ms. Heather Blaber | Senior Vice President of Marketing | — |
| Mr. Roger L. Storms | Senior Vice President of Sales | — |
| Ms. Pamela Wilson BA | Senior Vice President of Clinical Operations | — |
| Dr. Petra Rietschel | Senior Vice President of Clinical Development | — |
| Mr. Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
1 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.3 | -21.2 | -45.7 | +1.3 | ||||||||
| 2022 | -22.9 | -11.9 | +22.6 | -20.8 | -16.0 | +52.4 | +5.4 | -7.9 | -9.5 | -8.8 | +100.9 | -7.2 |
| 2023 | +4.1 | -11.3 | -23.1 | -11.6 | +26.9 | +2.6 | +10.7 | +2.3 | -28.9 | -3.9 | +47.2 | +15.5 |
| 2024 | +3.8 | +27.2 | -10.0 | -4.0 | -22.2 | -14.0 | +9.5 | |||||
| 2025 | +6.4 | |||||||||||
| 2026 | -25.8 | -0.5 | +11.1 | -4.3 | +13.9 | -0.8 | +18.5 | +4.5 |



